



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/808,732	03/14/2001	Richard F. Hammen	A-69071/RFT	5501

7590 05/13/2003

FLEHR HOHBACH TEST ALBERITTON & HERBERT LLP
Suite 3400
Four Embarcadero Center
San Francisco, CA 94111-4187

EXAMINER

THERKORN, ERNEST G

ART UNIT PAPER NUMBER

1723

DATE MAILED: 05/13/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/808,732	HAMMEN	
	Examiner THERKORN	Art Unit 1723	
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --			
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.			
<ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 			
Status			
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>April 23, 2003</u> .			
2a) <input checked="" type="checkbox"/> This action is FINAL . 2b) <input type="checkbox"/> This action is non-final.			
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims			
4) <input checked="" type="checkbox"/> Claim(s) <u>1-8, 12, and 26</u> is/are pending in the application.			
4a) Of the above, claim(s) _____ is/are withdrawn from consideration.			
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.			
6) <input checked="" type="checkbox"/> Claim(s) <u>1-8, 12, and 26</u> is/are rejected.			
7) <input type="checkbox"/> Claim(s) _____ is/are objected to.			
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.			
Application Papers			
9) <input type="checkbox"/> The specification is objected to by the Examiner.			
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.			
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120			
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of: 1. <input type="checkbox"/> Certified copies of the priority documents have been received. 2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).			
*See the attached detailed Office action for a list of the certified copies not received.			
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) <input type="checkbox"/> The translation of the foreign language provisional application has been received.			
15) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s)			
1) <input type="checkbox"/> Notice of References Cited (PTO-892)		4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____	
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)	
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____		6) <input type="checkbox"/> Other: _____	

Art Unit: 1723

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-6 and 8 are rejected under 35 U.S.C. 103(a) as obvious over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) in view of Frechet (U.S. Patent No. 5,334,310). At best, the claims differ from each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in reciting use of a functional group. Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. It would have been obvious to use a functional group in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) because Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound.

Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) as applied to claims 1-6 and 8 above, and further in view of Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279. At best, the claim differs from each of Good (U.S. Patent No. 3,808,125) and Fuller

Art Unit: 1723

(U.S. Patent No. 3,878,092) in reciting use of a capping agent. Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279 discloses “capping” ensures optimum surface coverage by organic groups. It would have been obvious to cap in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) because Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279 discloses “capping” ensures optimum surface coverage by organic groups.

Claims 12 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) in view of Frechet (U.S. Patent No. 5,334,310) as applied to claims 1-6 and 8 above, and further in view of Larson (U.S. Patent No. 5,723,601). At best, the claims differ from each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Frechet (U.S. Patent No. 5,334,310) in reciting use of an enzyme. Larson (U.S. Patent No. 5,723,601) (column 1, lines 25-28, column 2, lines 47-50, column 4, lines 2-16) discloses that enzymes are desirable functional groups for continuous beds. It would have been obvious to use an enzyme in each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Frechet (U.S. Patent No. 5,334,310) because Larson (U.S. Patent No. 5,723,601) (column 1, lines 25-28, column 2, lines 47-50, column 4, lines 2-16) discloses that enzymes are desirable functional groups for continuous beds.

The remarks urge patentability based upon the allegation that there is no motivation to use Frechet (U.S. Patent No. 5,334,310)’s functional groups in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092). However, Frechet (U.S. Patent No.

Art Unit: 1723

5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. As such, motivation exists to use a functional group in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) because Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound.


THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this

Art Unit: 1723

final action.

Any inquiry concerning this communication should be directed to E. Therkorn at telephone number (703) 308-0362.



**Ernest G. Therkorn
Primary Examiner
Art Unit 1723**

EGT/12
May 12, 2003